- Email: [email protected]
Prevalence of Metabolic Syndrome in Patients With Pulmonary Hypertension
October 2014, Vol 146, No. 4_MeetingAbstracts
Pulmonary Vascular Disease | October 2014
Prevalence of Metabolic Syndrome in Patients With Pulmonary Hypertension Ahmed Elshazly, MBBCh; Kamonpun Ussavarungsi, MD; Colleen Thomas, MS; Charles Burger, MD Pulmonary Medicine, Mayo Clinic, Jacksonville, FL
Chest. 2014;146(4_MeetingAbstracts):852A. doi:10.1378/chest.1978375
Abstract SESSION TITLE: Pulmonary Hypertension (Poster Discussion) SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM PURPOSE: Metabolic syndrome (MetS) may be a phenotypical risk for group 2 pulmonary hypertension (PH). This study compared the prevalence of MetS in patients with and without PH and by PH subgroup.
METHODS: Retrospective collection of demographics and clinical data for patients referred to Mayo Clinic Florida for PH since 1990, including comorbidities, functional class (FC), 6 minute walk distance (6MWD). MetS was defined as at least 3 of the following: systemic hypertension, diabetes mellitus, hyperlipidemia, or BMI > 30. A subgroup of patients that did not have PH served as a control.
RESULTS: Of 1287 patients, 1100 had PH and 187 did not. For PH, median (range) age was 67 years (15-93), 694 (63%) were women and 955 (87%) Caucasian. Diagnostic categories were: Group 1.1 Idiopathic pulmonary arterial hypertension (PAH), n=178 (16%); Group 1.2-1.4 Associated PAH, n=277 (25%); Group 2, n=324 (30%); Group 3, n=245 (22%); Group 4, n=57 (5%); and Group 5, n=19 (2%). 60% had FC III and 6MWD was 287 m (8-561). MetS was equally prevalent in 51 of 187 (27%) patients without PH (control) and 301 of 1100 (27%) of the PH patients: 22% in group 1.1 IPAH, 18% in group 1.21.4 APAH, 39% in group 2, 29% in group 3, 19% in group 4, and 16% in group 5. After adjusting for age, gender and race in logistic regression analysis, there was no evidence of a difference in MetS prevalence between PH patients and controls (adjusted OR=0.86, 95% CI: 0.61-1.24, p=0.42). Interestingly, group 2 PH had a higher prevalence of MetS when compared to group 1.1 IPAH even with adjustment for age, gender and race (adjusted OR=1.8, 95% CI: 1.17-2.79; p=0.008).
CONCLUSIONS: In this single-center, retrospective review, the prevalence of MetS was observed in 27% of patients with and without PH; however, among PH patients, the prevalence was higher in group 2 PH.
CLINICAL IMPLICATIONS: MetS is commonly present in PH patients, particularly group 2; however, the exact relationship remains ill-defined. DISCLOSURE: The following authors have nothing to disclose: Ahmed Elshazly, Kamonpun Ussavarungsi, Colleen Thomas, Charles Burger No Product/Research Disclosure Information
Pulmonary Vascular Disease | October 2014
Prevalence of Metabolic Syndrome in Patients With Pulmonary Hypertension Ahmed Elshazly, MBBCh; Kamonpun Ussavarungsi, MD; Colleen Thomas, MS; Charles Burger, MD Pulmonary Medicine, Mayo Clinic, Jacksonville, FL
Chest. 2014;146(4_MeetingAbstracts):852A. doi:10.1378/chest.1978375
Abstract SESSION TITLE: Pulmonary Hypertension (Poster Discussion) SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM PURPOSE: Metabolic syndrome (MetS) may be a phenotypical risk for group 2 pulmonary hypertension (PH). This study compared the prevalence of MetS in patients with and without PH and by PH subgroup.
METHODS: Retrospective collection of demographics and clinical data for patients referred to Mayo Clinic Florida for PH since 1990, including comorbidities, functional class (FC), 6 minute walk distance (6MWD). MetS was defined as at least 3 of the following: systemic hypertension, diabetes mellitus, hyperlipidemia, or BMI > 30. A subgroup of patients that did not have PH served as a control.
RESULTS: Of 1287 patients, 1100 had PH and 187 did not. For PH, median (range) age was 67 years (15-93), 694 (63%) were women and 955 (87%) Caucasian. Diagnostic categories were: Group 1.1 Idiopathic pulmonary arterial hypertension (PAH), n=178 (16%); Group 1.2-1.4 Associated PAH, n=277 (25%); Group 2, n=324 (30%); Group 3, n=245 (22%); Group 4, n=57 (5%); and Group 5, n=19 (2%). 60% had FC III and 6MWD was 287 m (8-561). MetS was equally prevalent in 51 of 187 (27%) patients without PH (control) and 301 of 1100 (27%) of the PH patients: 22% in group 1.1 IPAH, 18% in group 1.21.4 APAH, 39% in group 2, 29% in group 3, 19% in group 4, and 16% in group 5. After adjusting for age, gender and race in logistic regression analysis, there was no evidence of a difference in MetS prevalence between PH patients and controls (adjusted OR=0.86, 95% CI: 0.61-1.24, p=0.42). Interestingly, group 2 PH had a higher prevalence of MetS when compared to group 1.1 IPAH even with adjustment for age, gender and race (adjusted OR=1.8, 95% CI: 1.17-2.79; p=0.008).
CONCLUSIONS: In this single-center, retrospective review, the prevalence of MetS was observed in 27% of patients with and without PH; however, among PH patients, the prevalence was higher in group 2 PH.
CLINICAL IMPLICATIONS: MetS is commonly present in PH patients, particularly group 2; however, the exact relationship remains ill-defined. DISCLOSURE: The following authors have nothing to disclose: Ahmed Elshazly, Kamonpun Ussavarungsi, Colleen Thomas, Charles Burger No Product/Research Disclosure Information